Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: 10.1038/s41598-023-30616-w
- Event
-
Veröffentlichung
- (where)
-
Aachen
- (who)
-
Universitätsbibliothek der RWTH Aachen
- (when)
-
2023
- Creator
-
Subramanyam, Sudheendra Hebbar
Hriczko, Judit Turyne
Pappas, Angeliki
Schippers, Angela
Wagner, Norbert
Ohl, Kim
Tenbrock, Klaus
- DOI
-
10.18154/RWTH-2023-03258
- URN
-
urn:nbn:de:101:1-2023041004370166058054
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Subramanyam, Sudheendra Hebbar
- Hriczko, Judit Turyne
- Pappas, Angeliki
- Schippers, Angela
- Wagner, Norbert
- Ohl, Kim
- Tenbrock, Klaus
- Universitätsbibliothek der RWTH Aachen
Time of origin
- 2023
Other Objects (12)
Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity
5 Jahre Tofacitinib bei Colitis ulcerosa
Leitliniengerechte Therapie mit Tofacitinib bei Colitis ulcerosa
Tofacitinib (Colitis ulcerosa) : Nutzenbewertung gemäß § 35a SGB V
Tofacitinib: An Option for Acute Severe Ulcerative Colitis?
Specific immunotherapy ameliorates ulcerative colitis
Tofacitinib : Januskinase-Inhibition als innovatives therapeutisches Prinzip bei Colitis ulcerosa
Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis
Tofacitinib (Xeljanz) : der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa
Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model
Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis
Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity
5 Jahre Tofacitinib bei Colitis ulcerosa
Leitliniengerechte Therapie mit Tofacitinib bei Colitis ulcerosa
Tofacitinib (Colitis ulcerosa) : Nutzenbewertung gemäß § 35a SGB V
Tofacitinib: An Option for Acute Severe Ulcerative Colitis?
Specific immunotherapy ameliorates ulcerative colitis
Tofacitinib : Januskinase-Inhibition als innovatives therapeutisches Prinzip bei Colitis ulcerosa
Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis
Tofacitinib (Xeljanz) : der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa
Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model
Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis
Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity
5 Jahre Tofacitinib bei Colitis ulcerosa
Leitliniengerechte Therapie mit Tofacitinib bei Colitis ulcerosa
Tofacitinib (Colitis ulcerosa) : Nutzenbewertung gemäß § 35a SGB V
Tofacitinib: An Option for Acute Severe Ulcerative Colitis?
Specific immunotherapy ameliorates ulcerative colitis
Tofacitinib : Januskinase-Inhibition als innovatives therapeutisches Prinzip bei Colitis ulcerosa
Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis
Tofacitinib (Xeljanz) : der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa
Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model